Shandong Boan Biotechnology Co., Ltd.

山东博安生物技术股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

Stock Code : 6955

2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Boan Biotech
博安生物

CONTENTS

1 DEFINITIONS

Unless otherwise stated in the Report, the following terms are defined as follows:

"Boan Biotech" or the "Company"	Shandong Boan Biotechnology Co., Ltd.
the "Group" or "we"	Shandong Boan Biotechnology Co., Ltd. and its subsidiaries
the "Board"	Board of Directors of the Company
"China"	People's Republic of China
"Hong Kong"	Hong Kong Special Administrative Region of the People's Republic of China
"CMO"	CMO manufacturers entrusted by Boan Biotech
"EHS"	Environment, Health and Safety
"ESG"	Environmental, Social and Governance
"ESG Committee" or "Committee"	Environmental, Social and Governance Committee
"ESG Guide"	Environmental, Social and Governance Reporting Guide set out in Appendix C2 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited issued by the Stock Exchange
"ESG Report" or the "Report"	Environmental, Social and Governance Report
"GMP"	Good Manufacturing Practice for Pharmaceutical Products
"GSP"	Good Supply Practice for Pharmaceutical Products
"KPI"	Key Performance Indicator
"QA"	Quality Assurance Department
"QC"	Quality Control Department
"RMB"	Renminbi yuan, the lawful currency of China
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Year" or "Reporting Period"	From 1 January 2024 to 31 December 2024

2 ABOUT THIS REPORT

This is the third publicly available ESG Report issued by the Company on Boan Biotech's ESG performance for the year 2024. Boan Biotech will disclose our environmental and social management policies, strategies, targets and performance indicators in various sections of this Report.

2.1 BASIS OF PREPARATION

The Company has prepared this Report in accordance with the ESG Guide issued by the Stock Exchange. The Report has been prepared pursuant to the four Reporting Principles set out in the ESG Guide, namely materiality, quantitative, balance and consistency. Boan Biotech has determined the key disclosures in the Report through materiality assessment.

2.2 REPORTING BOUNDARY

Unless otherwise specified, the content of this Report primarily covers the core business having financial significance to and operational impact on Boan Biotech, which is intended to report on Boan Biotech's environmental and social policies and performance. This Report covers the period from 1 January 2024 to 31 December 2024.

2.3 REPORTING PRINCIPLES

The four reporting principles set out in the ESG Guide have been applied in this Report as follows:

Reporting Principles	Response from the Group
Materiality	The Company has identified material issues related to the Company through materiality assessment, including inviting various internal and external stakeholders to prioritise the material issues and presenting them in the form of a materiality matrix in this Report. For details of the materiality assessment process and results, please refer to the "Materiality Analysis" section in this Report.
Quantitative	In order to comprehensively assess the Company's ESG performance during the Reporting Period, the Company disclosed the applicable quantitative KPIs specified in the ESG Reporting Guide, and set out the criteria, methodologies, assumptions and references used for calculation of the quantitative KPIs, including the sources of key conversion factors.
Balance	The Report provides an unbiased picture of the Company's performance during the Reporting Period, and avoids selections, omissions, or presentation formats that may inappropriately influence a decision or judgment by the report reader.
Consistency	The Report is the third publicly available ESG Report issued by the Company, using consistent calculation and statistical methodologies and maintaining alignment with pre-listing standards. We will note and explain any changes (if possible) in the footnotes.

2.4 CONSIDERATION AND APPROVAL OF THE REPORT

All information disclosed in this Report is based on the Company's documents and data. The Board assumes full responsibility for the Company's ESG strategy and reporting.

Upon review and confirmation by the Board, this Report was considered and approved on 27 March 2025.

2.5 READER'S FEEDBACK

If readers have any comments on Boan Biotech's ESG Report or related work, please feel free to contact Boan Biotech by the following means:

Address:
Shandong Boan Biotechnology Co., Ltd.
No. 39 Keji Avenue, High-Tech Industrial Development Zone, Yantai, Shandong Province, China

3 ABOUT BOAN BIOTECH

3.1 COMPANY PROFILE

Boan Biotech (6955.HK) is a fully-integrated biopharmaceutical company developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The Company's drug discovery activities revolve around multiple platforms: Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform, ADC Technology Platform and Cell Therapy Platform.

Boan Biotech operates across the entire value chain of the industry covering antibody discovery, cell line development, upstream and downstream process development, analytical and bio-analytical method development, technology transfer, non-clinical research, clinical research, regulatory affairs and registration, and commercial production. In the cell therapy field, Boan Biotech focuses on a new generation of enhanced and regulated CAR-T technology, developing safer, more effective, and affordable treatments.

Boan Biotech has a pipeline of biosimilar products and novel biologics with global intellectual property rights. Among them, three biologics have been approved for marketing, two biologics are under biologics license applications review. The Company has been recognized as a "National High-tech Enterprise" and possesses provincial technology platforms such as "Shandong Provincial New R&D Institution" and "Shandong Provincial Engineering Research Center". In addition to China, the Company is also developing biopharmaceutical products in overseas markets, including the U.S., the EU and Japan. With a differentiated portfolio and well-established commercial capabilities, Boan Biotech operates across the industry's value chain from research and development to manufacturing and commercialization, laying a solid foundation for long-term, high-quality growth in the future.



3.2 HONOURS AND RECOGNITION

Four major international standard certifications, ISO9001/ISO14001/ISO45001/ISO50001

After strict review and evaluation by esteemed certification bodies, Boan Biotech has passed the three major international standard certifications, being ISO9001, ISO14001, and ISO45001. These certifications are testaments to the Company's outstanding performance and management standards in terms of quality, environment and occupational health and safety management system. Moreover, in 2024, Boan Biotech obtained ISO50001 certification for its Energy Management System for the first time. The Company has integrated an energy management system into its EHS framework and established a dedicated digital management platform.

Boan Biotech Retains EBC "Innovation Breakthrough Enterprise" Award

In March 2024, the 9th Enmore BIOCHINA (EBC) International Convention held in Suzhou announced the "EBC Awards" series of accolades. These awards were selected by the EBC organizing committee and expert panel through an evaluation of companies' annual performance and industry competitiveness in 2023. Boan Biotech was once again honored with the "Innovation Breakthrough Enterprise" award, recognizing its solid innovation capabilities and forward-looking strategic planning.

Boan Biotech Recognized as a "Provincial Digital Facility in Shandong"


山东省工业和信息化厅

关于2024年山东省级智能工厂、数字化车间、智能制造场景和系统解决方案供应商名单的公示

附件 2：

2024 年省级数字化车间名单

序号	所在市	企业名称	车间名称	类型
31	烟台市	山东博安生物技术股份有限公司	数字化生物再生产车间	数字化车间

In August 2024, Boan Biotech was successfully recognized as a "Provincial Digital Facility in Shandong." In recent years, Boan Biotech has consistently prioritized smart manufacturing as a key driver of high-quality development, increasing support for digital transformation and intelligent upgrades. The Company has continuously promoted process innovation, equipment upgrades, management optimization, and the intelligentization of production processes, thereby unlocking new growth momentum.

Boan Biotech Successfully Included in the National-level "Little Giant" List of Specialized and Sophisticated SMEs


山东省工业和信息化厅

关于山东省第六批专精特新“小巨人”企业和第三批专精特新“小巨人”复核通过企业名单的公示

附件1

第六批专精特新“小巨人”企业公示名单

序号	省（区、市）	企业名称
42	山东省	山东博安生物技术股份有限公司

In September 2024, Boan Biotech was included in the "Little Giant" list of specialized and sophisticated SMEs. The selection process of the list, organized by the Ministry of Industry and Information Technology of the PRC, aims to nurture outstanding small and medium-sized enterprises through coordinated policies in taxation, finance, technology, industry, and talent, providing full-chain support for innovative development of the enterprises to further enhance industrial chains and competitiveness. With its outstanding innovation capabilities, high-level core technologies, significant market share, and strong quality performance, Boan Biotech has emerged as a leading enterprise in the biopharmaceutical sector.

Boan Biotech Honored as "Shandong Provincial Enterprise Technology Center 2024"


2024年度山东省企业技术中心拟认定公示名单

序号	企业技术中心所在企业名称	企业技术中心名称
119	山东博安生物技术股份有限公司	山东博安生物技术股份有限公司技术中心

In November 2024, the Shandong Provincial Development and Reform Commission released the "Shandong Provincial Enterprise Technology Center 2024" list, with Boan Biotech successfully making the cut. This recognition as a "Shandong Provincial Enterprise Technology Center" serves as authoritative acknowledgment of Boan Biotech's exceptional technological innovation capabilities, remarkable innovation achievements, and its exemplary role in driving industry progress.

4 RESPONSIBLE OPERATIONS

4.1 SUSTAINABLE DEVELOPMENT CONCEPT

4.1.1 Governance Structure

Boan Biotech is committed to realising the vision of "becoming a leading biopharmaceutical company", and takes a leading role in pharmaceutical research and development and sustainable progress. We actively integrates the concept of sustainable development into its strategic planning and operational practices. By incorporating ESG factors into our governance system, we effectively monitor and manage Boan Biotech's performance in sustainability Boan Biotech is committed not only to pursuing economic benefits but also to fulfilling its social responsibilities, ensuring transparency and compliance in corporate governance to achieve long-term sustainable development goals.

4.1.2 ESG Governance and Risk Management of the Board

As the highest governing body for ESG issues of the Company, the Board has the overall supervision responsibility for the formulation of ESG governance strategy and targets and reporting. Its responsibilities include reviewing and approving ESG-related policies, overseeing the progress of ESG target implementation, and ensuring the Company's ESG performance aligns with established standards and expectations.

4.1.3 ESG Committee

The Board supervises and manages the Group's ESG governance work through the ESG Committee. Through the establishment of a dedicated ESG Committee, the Company has ensured a high level of attention to, and effective management of, ESG aspects. The ESG Committee, authorised by the Board, is responsible for:

(1) Overseeing the effectiveness of the Group's policies and strategies in ESG, and conducting regular reviews on the strategy, progress and performance of sustainable development;

(2) Identifying ESG risks and opportunities, and reviewing the effectiveness of the Group's risk management and internal control systems;

(3) Setting business-related ESG targets, while monitoring the implementation and progress of these targets;

(4) Reporting to the Board on the management of ESG targets and providing relevant recommendations.

The Board has selected two directors to join the ESG Committee and designated one of them as the chairperson. The ESG Committee holds at least one formal meeting annually and, where required, convenes ad hoc meetings by the chairperson to assess and guide the Group's ESG management strategies and practices. The Committee regularly monitors the implementation of ESG policies, evaluate their effectiveness, and prepare and review the annual ESG report and other related disclosures.

Furthermore, the Committee conducts regular assessments of the Group's performance on key ESG issues, reviews progress towards the achievement of targets through annual and special reports, and provides recommendations on actions required to meet these targets. The relevant management status and progress shall be regularly reported to the Board to continuously drive performance improvement in the ESG management of the Group. Based on the recommendations and reports of the Committee, the Board assumes supervisory responsibility by providing necessary guidance and support to achieve ESG targets, thereby ensuring effective governance and continuous advancement of the ESG performance of the Group.

4.1.4 ESG Working Group

The ESG Committee has set up an ESG Working Group to assist the Committee in coordinating and managing the Group's ESG issues and coordinating the implementation and execution of ESG-related work across various functional departments, including strategic development, supply chain management, administration and R&D project management, manufacturing, environmental and occupational health and safety, human resources, patents, laws, finance, etc. Its functions include:

(1) assessing, prioritising and managing material ESG-related issues, including identifying ESG risks related to the Group's business;

(2) assisting in setting ESG targets and related work plans to ensure alignment with the Group's strategic direction;

(3) conducting periodic reviews of ESG target progress, preparing lists and analysis reports on material issues for the Committee' consideration;

(4) recommending appropriate and effective ESG risk management and internal control measures.

4.2 STAKEHOLDER ENGAGEMENT

Boan Biotech expects this Report to serve as a bridge for communicating with various stakeholders and to respond to the concerns of the public and industry by reporting on our annual progress in achieving the sustainable development. During the year, Boan Biotech has conducted an in-depth questionnaire survey among stakeholders, gaining a comprehensive understanding of their perspectives and the emphasis they place on key issues such as environmental protection, employee welfare and corporate operations. Throughout this process, open and transparent communication with all parties has been maintained.

In this Report, we place special emphasis on the main ESG concerns identified in 2024, ensuring that our efforts towards sustainable development remain aligned with the expectations and needs of our stakeholders.

Case: Boluojia Launch Celebration Event

Case: 2024 Yangzhou Biopharmaceutical Innovation & Development Summit

In April 2024, the "2024 Yangzhou Biopharmaceutical Innovation & Development Summit" was held under the theme "Forging New Quality Productivity in Biopharmaceuticals." The event brought together industry leaders and pioneers for in-depth discussions. As one of the keynote speakers for the "GLP-1 Drug Innovation & Development" session, Boan Biotech was represented by Senior Director Song Deyong, who shared insights on the development progress and experience of an innovative GIPR/GLP-1 antibody-peptide drug conjugate. This presentation not only demonstrated Boan Biotech's innovation capabilities in biopharmaceuticals but also provided valuable opportunities for technical exchange and collaboration within the industry.

Case: Partnering to Explore Digital Innovation in Pharmaceuticals

In September 2024, Boan Biotech and Qingdao Haier Biomedical Co., Ltd. signed a strategic cooperation agreement in Qingdao. The two parties will engage in deep cooperation in digitalization, automation, and AI-integrated innovation to drive digital transformation in the pharmaceutical industry and accelerate the commercialization of R&D achievements. Through resource sharing and complementary strengths, the parties aim to jointly expand their product and service offerings.

4.2.1 Communication with Stakeholders

Boan Biotech consistently regards establishing solid and proactive connections with all stakeholders as a core mission. By implementing open and efficient communication channels, we are committed to deeply understanding our partners' needs and suggestions while accurately identifying potential challenges and development opportunities in the ESG field. These efforts are designed to provide robust support for the Company's long-term sustainable development strategy and drive continuous progress and innovation in the ESG field.

The expectations of our stakeholders for us and our routine communication channels with them are as follows:

Main Stakeholders	Expectations	Communication Methods
Government and regulatory bodies	• Compliance with laws and regulations • Strengthening R&D of pharmaceutical technologies	• Optimising the legal risk prevention and control system • Vigorously investing in R&D of drugs
Investors	• Good operational management to reduce operational risks • Good return on investment • Transparent information disclosure • R&D ethics	• Regularly holding results announcement conferences and general meetings of shareholders • Optimising the legal risk prevention and control system • Regularly updating the website to ensure the investors have access to the latest information of the Company • Regularly organising investor survey and company day events • Regularly participating in strategy sessions and roadshows
Customers	• Providing safe and high-quality medicines • Constantly developing new drugs • Protecting consumers' rights and interests	• Vigorously investing in R&D of drugs • Improving the drug production management system • Conducting customer satisfaction surveys
Employees	• Good working environment • Good career prospects	• Providing good remuneration • Organising various training activities • Organising various employee activities • Providing a safe working environment
Partners/suppliers	• Mutual cooperation for win-win results	• Actively seeking superior suppliers and CMO/CDMO partners
Peer companies	• Promoting industry development	• Actively organising and participating in industry forums and exchange events
Non-governmental organisations	• Constantly developing new drugs	• Vigorously investing in R&D of drugs
Media	• Transparent information disclosure	• Regularly updating the website to ensure the public have access to the latest information of the Company • Release of major business progress via news or WeChat official account

4.2.2 Materiality Assessment

In order to respond to the sustainability needs of various stakeholders, and to effectively manage and report on issues that have a significant impact on us and our stakeholders, we conducted materiality assessment during the year to determine the scope of our disclosure priorities for this Report. The specific assessment process is described as follows:



We invited internal stakeholders (the Board and senior management) and external stakeholders (employees, partners, investors and the public) to participate in this materiality survey to thoroughly discuss their opinions on the Group's ESG issues in three major aspects, including environment, labour, and operations. In this questionnaire, we received 33 valid responses, based on which we conducted detailed analysis and developed materiality issues matrices. The following presents the materiality analysis matrices of ESG issues for 2024, with the high material issues in the upper right quadrant of the matrix:



2024 Materiality Issues Matrices for Environmental Responsibility of Boan Biotech



2024 Materiality Issues Matrices for Labour Responsibility of Boan Biotech



2024 Materiality Issues Matrices for Operational Responsibility of Boan Biotech

After reviewing and confirming the analysis results of material issues, the Group has identified a total of 17 material issues. Such issues will be taken as important considerations for our future sustainability direction and are also the focus of disclosures in this Report.

Material Issues (in the order of importance from top to bottom)

Environmental Responsibility	**Labour Responsibility**	**Operational Responsibility**
Waste discharge and management	Employee salaries and benefits	Product R&D and innovation
Water resource use efficiency and wastewater discharge management	Occupational health and safety system training	Pharmaceutical production quality and therapeutic efficacy governance system
Chemicals management	Diversity, equality, inclusiveness and sense of belonging	Business growth
Green manufacturing system during the product lifecycle	Employee training and development	Operational compliance
Air pollutant emission and management	Employee recruitment policy	Safe production and emergency response procedures
Energy use		Risk management

4.3 INTEGRITY AND COMPLIANCE

Fully aware of the significance of fostering a fair and incorruptible business environment and ethical culture, the Company has always prioritized anti-corruption efforts as a core focus of its management. Strictly adhering to relevant laws and regulations, including the Criminal Law of the People's Republic of China, the Anti-Money Laundering Law of the People's Republic of China, and the Law of the People's Republic of China Against Unfair Competition, we have established strict codes of business conduct targeting bribery, extortion, fraud and money laundering, which are applicable to all our employees and partners. During the Reporting Period, the Group did not receive any reports of violations or illegal activities related to bribery, extortion, fraud and money laundering. Nor were there any material breaches of anti-corruption related laws and regulations or concluded corruption-related legal cases. This reflects our effective management and ongoing efforts in anti-corruption as well as our firm commitment to integrity in business operations.

4.3.1 Anti-Corruption Policies and Preventive Measures

Boan Biotech has always been committed to continuously elevating the standards of integrity and compliance, actively constructing and optimizing our internal management policies and risk management mechanisms. Our corruption management system encompasses numerous key policies, such as the Anti-Fraud and Anti-Bribery Policy, aiming to ensure the transparency and integrity of the Company's operations. This policy applies to all directors, senior management, employees, agents, consultants, partners and other relevant personnel, clearly defining the boundaries of conduct for each party in business activities and strictly prohibiting any form of improper transfer of benefits. Violation of this policy may result in disciplinary actions by the Company, including demotion, suspension or dismissal. In cases of serious violations that breach mandatory regulations, the Group will initiate the case referral process in accordance with the laws and report the policy violations to the relevant regulatory or law enforcement authorities.

To enhance the effectiveness of internal supervision, we provide multiple reporting channels for employees and partners, including telephone, email (with a dedicated anti-corruption reporting mailbox: boanethics@boan-bio.com), and written correspondence. We accept both named and anonymous reports. Upon receiving a report, we may assign a dedicated person to handle it and strictly keep all reported information and investigation records confidential to ensure the privacy and safety of the whistleblower. Depending on the severity of the incident, we may take disciplinary actions against the employees involved, including written warnings, suspension and dismissal if a violation is confirmed.

Handling procedures of the Audit Department or the Chairman of the Audit Committee upon receipt of a whistleblowing report

1 Confirm the receipt of a whistleblowing report;

2 Inform the whistleblower on whether the whistleblowing case will be further investigated, and where appropriate, inform the whistleblower of the actions taken or to be taken, or the reasons why no investigation has been made in respect of the whistleblowing case;

3 If feasible, provide an estimated timetable for the investigation and final response; and

4 Indicate whether any remedial or legal action has been or will be taken, and provide feedback to the whistleblower on the investigation and handling results.

We are acutely aware of the importance of upholding principles against corruption and bribery in our cooperation with business partners and agents. Under the cooperation agreements, all our agents shall undertake to assume the obligation to comply with anti-corruption and anti-bribery measures, including strict compliance with relevant local laws and regulations. During the Reporting Period, there were no allegations of corruption, embezzlement, or bribery against any agents due to the involvement in the sales of our products. This not only reflects our stringent requirements in partner management but also demonstrates our joint efforts with agents to uphold an environment of integrity in business operations.

4.3.2 Anti-Corruption Training Measures

To continuously enhance the compliance awareness among management and staff, and to ensure the effective implementation of the Company's compliance policies, a series of compliance training courses have been provided for both management and staff. These courses cover key areas such as anti-corruption, anti-bribery, data protection, professional ethics and relevant laws and regulations, aiming to enhance employees' understanding of compliance requirements and their ability to implement them. Through these trainings, we have not only raised the compliance awareness of all employees but also further strengthened the compliance culture within the Company, ensuring that all business activities are in line with laws, regulations and ethical standards. We conducted anti-corruption training for the Board and employees in 2023, but no training was arranged in 2024. The Legal Department will continue to deepen employees' professional knowledge in anti-corruption and compliance management in a more systematic manner in the future.

5 CONTINUOUS INNOVATION

Boan Biotech focuses on exploring, developing, manufacturing and marketing innovative biological products, and is committed to becoming a global leader in the field of biopharmaceuticals. In terms of R&D system, we possess a series of independently developed drug candidates and proprietary technology platforms, becoming one of the few pharmaceutical companies in China capable of independently completing the entire process from early drug research to commercialization.

With profound expertise and extensive industry experience, our R&D capabilities span several key areas, including antibody discovery, cell line development, upstream and downstream process development, analytical method development, technology transfer, pilot production and commercial production. These core competencies not only support our efficient advancement of innovative drug development but also provide a solid foundation for the Company's competitiveness in the global biopharmaceutical field. Looking ahead, we will continue to invest in R&D innovation, driving the development and application of more breakthrough therapies to bring more treatment options and hope to patients.

Product Images of Boyounuo®, Boyoubei® and Boluojia®

5.1 PRODUCT INNOVATION & PROTECTION OF SCIENTIFIC RESEARCH ACHIEVEMENTS

Boan Biotech is committed to the research and development of biosimilars and advanced biological products, gathering leading talents in biotechnology and collaborating with numerous industry partners. Innovation and excellence form the cornerstone of our development strategy, as we consistently enhance our technology platforms to deliver a robust technological foundation and innovation impetus for new drug development. The Company's research and development capabilities are mainly based on platforms for antibody development and cell therapy technologies, which provide powerful technical backing and innovation drivers across all critical phases of new drug development, including early research, preclinical studies, clinical trials and commercial production. In the future, we will further deepen the development of these technology platforms to drive the development and application of more transformative therapies.

Antibody R&D Technology Platforms	**Human Antibody Transgenic Mouse and Phage Display Technology Platform** • **BA-huMab® Platform** o Contains 30 human antibody κ light chain variable region genes, and 110 human antibody heavy chain variable region genes (IgM&IgG1) o Can directly generate human antibodies without humanization, to accelerate the antibody discovery process and reduce the immunogenicity risk o Elicits an immune response quickly and produce a high antibody tier after immunization o Verified on a large number of antibody projects • **Phage Display Technology Platform** o Adopts new vaccine and immune adjuvant technology o Efficient animal immunization technology o Mature phage library construction technology o High-throughput and diverse phage based panning strategies o Diversified evaluation capabilities for antibodies or antibody fragments
	Bispecific T-cell Engager Technology Platform o High affinity with tumor target antigen by bivalent binding to achieve better drug efficacy o Low affinity with T cells by monovalent binding to lower toxicity o Reduces CD3 antibody binding affinity which significantly reduces the risk of CRS o Develops a CD3 trispecific antibody targeting two tumor antigens which can kill highly heterogeneous tumors more efficiently
	ADC Technology Platform o Design, synthesis, and screening of potential ADC linker-payloads o Discovery of antibodies with internalization potential o Diverse antibody conjugation methods o In vitro and in vivo ADC evaluation o Process development and quality analysis for ADC products

Cell Therapy Technology Platform	**Non-Viral Gene Delivery Process Platform** o Free from virus research and production limitations, saving costs and development cycles o The large load can accommodate multiple functional structural genes to achieve efficient transduction o The population of stem-like cells is higher in proportion and more durable in vivo
	4th Gen CAR-T Technology • **Enhanced CAR-T** o To overcome the limitations of the tumor microenvironment, multiple structures that enhance T cell function were selected • **STEALTH™ CAR-T** o Dual-target CAR kills antigenically heterogeneous tumors o The function of "primary action CAR structure" and "secondary action CAR structure" is regulated to reduce the target risk
	Non-Gene-Edited Universal CAR-T Technology o The expression of TCR was down-regulated with "ReceptorTAC™" protein degradation technology o Simple and efficient, CAR transduction and TCR down-regulation can be achieved in one step o Good safety, no off-target risk associated with gene editing o Developed with proprietary IP, the technology can be expanded to other cell therapy products

We fully recognize the pivotal role that the construction and maintenance of intellectual property rights play in ensuring the long-term development of the Company. To protect our innovative achievements, we have established a dedicated Intellectual Property Department to ensure that the concept of intellectual property management is deeply embedded in every stage, from research and development to manufacturing and marketing. This strategic approach not only helps maintain our industry-leading technological position but also provides robust protection for the Company's commercial interests and legal rights.

Boan Biotech strictly adheres to the relevant intellectual property laws of the People's Republic of China, including the Patent Law of the People's Republic of China, the Trademark Law of the People's Republic of China and other regulations. To further strengthen internal management, we have established a series of detailed internal systems, including the Intellectual Property Workflow of Shandong Boan Biotechnology Co., Ltd. and the Patent Management System of Shandong Boan Biotechnology Co., Ltd., to ensure comprehensive protection of intellectual property and strict enforcement of relevant regulations.

In the Patent Management System of Shandong Boan Biotechnology Co., Ltd., we have specified all aspects of patent management, including the allocation of responsibilities within the Company's patent work organization, the management and implementation of patent rights, and the utilization of patent information. Meanwhile, the Intellectual Property Workflow of Shandong Boan Biotechnology Co., Ltd. covers the management of intellectual property in various fields, including patents, trademarks, copyrights, and know-hows. It includes application processes, rights evaluation and search procedures, with the aim of establishing a professional, standardized and systematic intellectual property management framework. These procedures help us to effectively mitigate intellectual property risks, enhance the value of the Company's intangible assets, and utilize resources more efficiently.

For our drug candidates, we have filed various patent applications worldwide to ensure the protection of patent rights in different countries and regions. In addition, our intellectual property protection strategy extends beyond patents to include trademarks, trade secrets and other forms of intellectual property, creating a comprehensive protection system to provide full legal protection and commercial competitiveness for the Company's innovative achievements. During the year, Boan Biotech has obtained 39 registered patents and has 45 pending patent applications worldwide. 83 PRC and overseas trademarks were validly licensed, while 4 trademarks were pending.

As at the end of the year, the number of patents and trademarks of Boan Biotech granted and pending in PRC and overseas is as follows:

Registered patents		
	Validly licensed patents	Validly pending patents
Domestic	29	11
Overseas	10	34

Registered trademarks		
	Validly licensed trademarks	Validly pending trademarks
Domestic	25	0
Overseas	58	4

Some patents granted to Boan Biotech in 2024

证书号第6645610号

发明专利证书

发 明 名 称：用于免疫治疗的T细胞双特异性抗体生产中的优化抗CD3臂

发 明 人：阿瓦尼许·瓦许尼;周立;依瑞娜·施耐德

专 利 号：ZL 2020 8 0082945.6

专利申请日：2020年12月15日

专 利 权 人：山东博安生物技术股份有限公司

地 址：264670 山东省烟台市高新区科技大道39号

授权公告日：2024年01月26日 授权公告号：CN 114829408 B

国家知识产权局依照中华人民共和国专利法进行审查，决定授予专利权，颁发发明专利证书并在专利登记簿上予以登记。专利权自授权公告之日起生效。专利权期限为二十年，自申请日起算。

专利证书记载专利权登记时的法律状况。专利权的转移、质押、无效、终止、恢复和专利权人的姓名或名称、国籍、地址变更等事项记载在专利登记簿上。

局长
申长雨

2024年01月26日

第1页(共2页)

其他事项参见续页

Patent Name: OPTIMIZED ANTI-CD3 ARM FOR THE PRODUCTION OF T-CELL BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPY
(Patent No.: ZL 2020 8 0082945.6)

Innovation, Sciences et Développement économique Canada
Innovation, Science and Economic Development Canada

Brevet canadien / Canadian Patent

3,136,281
Numéro de brevet
Patent number

Titre de l'invention / Title of invention
ANTICORPS OU RECEPTEUR ANTIGENIQUE CHIMERIQUE CIBLANT LA CLAUDINE 18.2

ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR WHICH TARGETS CLAUDIN 18.2

Breveté(s) / Patentee(s)
SHANDONG BOAN BIOTECHNOLOGY CO., LTD.

Inventeur(s) / Inventor(s)
SONG, DEYONG; ZHOU, LI; DONG, CHUANGCHUANG; NING, ZHENFEI

Le commissaire aux brevets a accordé un brevet pour l'invention décrite dans le mémoire descriptif portant le numéro de brevet susmentionné. Le mémoire descriptif est accessible dans la Base de données sur les brevets canadiens sur le site Web de l'Office de la propriété intellectuelle du Canada.

The Commissioner of Patents has granted a patent for the invention described in the specification under the above-noted patent number. The specification is accessible in the Canadian Patents Database on the website of the Canadian Intellectual Property Office.

Date de l'octroi et de la délivrance du brevet / Patent grant and issue date
2024-06-25

Date de dépôt de la demande / Filing date of the application
2020-05-28

Date d'accessibilité au public / Date application open to public inspection
2020-12-03

Commissaire aux brevets
Commissioner of Patents

PATENT OFFICE · BUREAU DES BREVETS · CANADA

(CIPO - 91) 2020-08-15

Canada

Patent Name: ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR WHICH TARGETS CLAUDIN 18.2
(Patent No.: 3,136,281)

5.2 PRODUCTION MANAGEMENT & QUALITY ASSURANCE

Boan Biotech has always regarded excellent quality as the core foundation of production management. We strictly adhere to the highest international recognized standards, leveraging our large-scale production capabilities to implement a rigorous quality management system throughout the entire supply chain, from raw material procurement, process control to finished product dispatch. This systematic quality control mechanism not only ensures the stability and reliability of product quality but also provides a solid support for the Company's core competitiveness, continuously driving our innovation breakthroughs and sustainable development in the biopharmaceutical field.

5.2.1 Quality Management System

Our production base located in Yantai High-Tech Zone, Shandong Province, specializes in the pilot and commercial production of antibody drugs, equipped with world-class biopharmaceutical production facilities and fully automated control systems. In terms of quality management, we have established an integrated quality management system that complies with China's Pharmaceutical Administration Law (revised in 2019), the Good Manufacturing Practice for Pharmaceutical Products (revised in 2010) and the EU GMP standards. This system has successfully passed the stringent reviews by the regulatory authorities in China and the EU. The Quality Manual we implement establishes a full lifecycle quality control mechanism, from the inspection of raw and auxiliary materials upon arrival, process control during production to the release of finished products, setting the quality goal of "continuously improving product quality and exceeding customer expectations."

GMP Pharmaceutical Quality Management System

Boan Biotech has established a comprehensive quality management system that covers the entire lifecycle of pharmaceutical products, from the research and development stage, technology transfer, commercial production, supply chain management to post-market monitoring, and controls all key factors that may affect the quality of drugs. Within this system framework, we have built a standardized management system, including a complete quality control documentation system, a comprehensive quality assurance mechanism, and strict risk control measures. By implementing these standardized requirements, we ensure that quality management standards are strictly enforced in every production link, providing all-round protection for product quality. At the same time, we regularly conduct system audits and continuous improvement work to continuously enhance product quality and compliance levels, keeping the quality management system in optimal condition. During the year, our innovative product Boluojia successfully passed the China GMP certification, which demonstrates the regulatory authorities' recognition of our quality management level. Looking ahead, we will continue to optimize the quality management system to ensure that we provide patients with safe, effective and stable quality drugs.

Quality Manual

The Company strictly complies with the requirements of the Pharmaceutical Administration Law and the Good Manufacturing Practice for Pharmaceutical Products and meets the standards of ISO9001:2015 – Quality management systems – Requirements, ICH Q10 Pharmaceutical Quality System and GMP. Based on these, we have developed the Quality Manual as the guiding document of the quality management system. The manual ensures the implementation of quality concepts through three main pathways: documentation control, process optimization and personnel training, providing a systematic guarantee for achieving the "high-quality" goal by embedding the quality philosophy into all levels of the organization and the entire business process. We regularly review and update the content of the manual to adapt to regulatory changes and technological development needs, continuously improving the quality management system.

5.2.2 Production Quality Assurance

Our production and operation team works closely with cross-functional teams including quality assurance, quality control, pharmacovigilance and supply chain management, strictly adhering to GMP standard operating procedures to produce products that are safe and meet high international quality standards. Throughout the entire production process, we not only fully comply with the requirements of international regulatory authorities such as the U.S. FDA and the European Medicines Agency, but also continuously exceed the regulatory standards of pharmaceutical regulations in various countries. During the year, we have further demonstrated our commitment to maintaining strict quality control measures and continuously optimizing production processes with an outstanding performance of zero deficiencies in the Brazilian GMP inspection.

5.3 DRUG SALES AND CUSTOMER SERVICE MANAGEMENT

During the research and production of drugs, we always adhere to the highest quality standards and strictly follow relevant laws and regulations to ensure the quality and safety of drug sales and customer service. We have fully compiled drug labels and instructions for use in strict accordance with the standards approved by the National Health Commission and the National Medical Products Administration, fully complying with the requirements of the Regulations on the Administration of Drug Instructions and Labels. In terms of advertising and promotion, we strictly implement the Pharmaceutical Administration Law of the People's Republic of China, follow the Measures for the Examination of Drug Advertisements and related regulations, and ensure that all advertising content is reviewed and approved by the relevant authorities and obtains an approval number before being released, resolutely eliminating any misleading or false publicity. Through these strict quality control measures, we ensure the accuracy and authenticity of all drug information and effectively safeguard patient safety.

5.3.1 Product Sales and Quality Management

The Company strictly complies with relevant Chinese pharmaceutical management regulations and has established a comprehensive product quality assurance system. In terms of quality control, we have formulated the "Sample Receiving, Inspection and Handling Procedures," which clearly defines the responsibilities of each party involved and implements full-process monitoring from sample receipt to the completion of inspection, establishing a complete quality inspection process that includes inspection, review and submission. For products that do not meet the standards, we strictly follow the Drug Return Handling Procedures, with the Company bearing all costs related to returns and exchanges to ensure that consumer rights are not harmed.

We place great emphasis on market feedback and have established a dedicated customer service team to handle consumer complaints via phone calls, with regular analysis and summarization of feedback information. The quality supervision team closely follows the progress of each complaint handling to ensure a rapid response and effective resolution to consumer concerns. In addition, in accordance with GMP and other regulatory requirements, we have formulated the "Drug Recall Management Regulations," which include detailed product recall operation guidelines, clear handling steps, specified responsible personnel to be notified and the disposal methods for recalled products. During the year, we have completed the revision of these regulations to further improve the recall process.

During the year, we received 3 product complaints, all of which were properly handled according to established standard procedures. There were no cases of product recalls due to quality issues during the year.

5.3.2 Information Security and Privacy Protection

Boan Biotech places high importance on the protection of personal information of customers and partners, strictly adhering to national laws and regulations such as the Personal Information Protection Law and fully implementing the Group's Personal Data Protection Policy. We have established a robust information security system through multiple protective measures: on the technical side, we apply advanced encryption to electronic data to ensure the confidentiality of personal data stored in electronic form; deploy state-of-the-art network security protection systems to ensure that only authorized personnel can access personal data; promptly destroy confidential waste documents that may contain personal data and regularly clean up personal data that exceeds the necessary time length. In addition, we regularly train relevant operators to help them gain a deep understanding of the personal data protection requirements applicable in their daily work. We are committed to continuously optimizing personal information protection mechanisms to ensure the confidentiality, integrity and availability of all personal data to the highest standards and effectively safeguard the legitimate rights and interests of customers and partners.

6 SUSTAINABLE SUPPLY CHAIN

Boan Biotech deeply recognizes that establishing a responsible and sustainable supply chain system is of key significance to achieving our ESG targets. We are committed to creating a supply chain that combines operational efficiency with ethical and environmental standards, thereby having a positive impact on society and the environment.

6.1 SUPPLY CHAIN FUNCTIONS

Our Supply Chain Management Team has the following four functions:

Functions of the Supply Chain Management Team of Boan Biotech

Business Planning	Procurement	Supply Chain Operations	Supply Chain Optimization
Development of supply and demand planning, as well as production and raw material planning	Procurement of equipment and materials for preclinical studies, clinical trials and manufacturing	Import and export customs declaration, transportation and storage of raw materials, clinical samples and drugs	Optimization of supply chain operations and management

6.2 SUPPLY CHAIN MANAGEMENT

The Company has established a comprehensive standardized supply chain management system that covers the entire process from procurement to supplier management. In terms of asset procurement, we have developed a strict approval procedure for the Asset Requisition List, requiring each department to complete the list and obtain written approval from the authorized financial officer and department head before proceeding with the procurement. This ensures that all procurement activities comply with the Company's regulations. For different types of procurement, we implement differentiated management: for direct procurement, we prioritize suppliers from the GMP-certified supplier list, and for indirect procurement, we strictly follows a bidding process to carefully select agents or distributors.

The supplier selection process employs a multidimensional comprehensive evaluation mechanism. In addition to considering basic elements such as price competitiveness and supply stability, we also take into account key indicators such as quality control systems, compliance records, corporate scale and strength, market reputation, and logistics costs in the assessment. This ensures that the selected suppliers can meet all of the Company's business needs. We place great emphasis on the sustainable development performance of suppliers, specifying environmental protection and social responsibility clauses in our supplier policies. We require cooperative suppliers to comply with local environmental regulations, implement pollution prevention measures, and continuously improve their environmental performance. During the supplier qualification review stage, in addition to verifying ISO system certification documents, we also use professional systems to check for any adverse records of potential partners, effectively managing environmental and social risks in the supply chain.

6 SUSTAINABLE SUPPLY CHAIN

Boan Biotech actively promotes green procurement, and has developed and implemented environmentally friendly procurement practices, including:

- When purchasing office supplies, give priority to products with environmental certification documents and environmental rating labels
- When purchasing electrical products used in offices or workshops, consider environmentally friendly products with low energy consumption (e.g. Class I energy efficiency), which are more energy efficient and environmentally friendly
- When purchasing office furniture, require the boards and substrates to meet the E0 level of the new international testing standard

Supplier Distribution of Boan Biotech in 2024

By geographical region	Domestic	Number	1,833
	Overseas	Number	79

During the year, Boan Biotech had a total of 1,833 domestic suppliers and 79 overseas suppliers, and the above supplier engagement practices apply to all suppliers to ensure the sustainability of our supply chain.

7 GREEN HOME

At Boan Biotech, the concept of sustainable development is deeply embedded in our corporate culture. Through systematic management measures such as the formulation of the Emergency Response Plan for Sudden Environmental Incidents and the implementation of the Environment, Health and Safety (EHS) Education Program, we continuously reduce the impact of our business operations on the environment and natural resources, striving to build a model green enterprise. We not only implement environmental protection concepts internally but also actively promote and work with our supply chain partners to implement environmental protection measures, promoting an environmentally friendly transformation across the entire industry chain.

In terms of operations, Boan Biotech's environmental management covers major facilities such as production bases, laboratories and offices, with environmental impacts mainly reflected in the treatment of hazardous and non-hazardous waste, energy consumption, greenhouse gas emissions and chemical management. Relevant environmental performance data have been fully presented in the Environmental KPIs Table in the appendix of this Report. During the year, we have strictly complied with national environmental regulations regarding air pollutant and greenhouse gas emissions, pollution prevention and control of water and soil, and the disposal of hazardous and non-hazardous wastes. There were no major environmental non-compliance events during the Reporting Period.

Boan Biotech complies with the following laws and regulations related to environmental protection and having a significant impact on us (including but not limited to):

- Environmental Protection Law of the People's Republic of China
- Environmental Protection Tax Law of the People's Republic of China
- Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste
- Law of the People's Republic of China on the Prevention and Control of Water Pollution
- Law of the People's Republic of China on Environmental Impact Assessment
- Law of the People's Republic of China on Energy Conservation
- Law of the People's Republic of China on the Prevention and Control of Environmental Noise Pollution
- Law of the People's Republic of China on the Prevention and Control of Soil Pollution
- Law of the People's Republic of China on the Promotion of Cleaner Production
- Renewable Energy Law of the People's Republic of China

In view of various major environmental factors, we have developed a number of environmental protection policies with reference to the applicable laws and regulations, some of which are shown as follows:

Major environmental factors	Internal policies of Boan Biotech (including but not limited to)
• **Hazardous and non-hazardous wastes**	• Waste Management Procedures • Toxic, Hazardous and Combustible Gas Leakage Detection and Alarming Management System
• **Environmental accidents**	• Emergency Response Plan for Sudden Environmental Incidents
• **Energy management**	• Energy and Resource Management Procedures
• **Noise**	• Noise Management and Control Procedures

7.1 GREEN OPERATIONS

Adhering to the philosophy of "focusing on environmental protection and ensuring sustainable development", Boan Biotech integrates green concepts into every aspect of corporate operations. From product design and manufacturing to final disposal, we strictly adhere to four major principles: "non-hazardous raw materials, clean production, waste resource utilization, and low-carbon energy," establishing a comprehensive environmental management system throughout the entire product lifecycle. By continuously optimizing production processes and resource allocation, we have not only effectively improved resource utilization efficiency but also achieved tangible results in energy conservation and emission reduction, fulfilling our social responsibility for environmental protection.

Categories	Management measures
Energy use	• Post environmental protection slogans on "Save Electricity" • Control the temperature of air conditioners and avoid running air conditioners and heaters during non-working hours • Turn off computer screens and other electrical equipment after work • Use low energy-consuming lighting fixtures (e.g. LED lights) • Purchase electrical appliances with energy labels (e.g. Class 1 energy label appliances)
Water resource use	• Post environmental protection slogans on "Save Water" • Promote awareness of water conservation and guide employees to use water rationally • Use water-saving systems and appliances (e.g. water-saving taps)
Office supplies	• Post 'Save Paper' signs in key locations • Encourage double-sided printing to reduce paper use • Promote paperless (OA) office work
Packaging materials	• Implement a packaging material recycling system

Case: Enhancing Electricity Conservation Management

Boan Biotech has achieved energy conservation and emission reduction through optimizing the electricity management of the air conditioning duty room. We implemented two specific improvement measures: first, turning off the lighting in the duty room during the day; second, strictly enforcing the policy of turning off monitors when computers are not in use. Calculations show that optimizing the electricity use of 13 computer monitors and 6 lights can save approximately 5,782 kWh of electricity annually, equivalent to reducing 3.10 tonnes of CO_2 emissions. This improvement not only implements the Company's energy-saving policy but also cultivates employees' awareness of energy conservation, providing a practical foundation for future energy efficiency enhancement plans in office areas.

Case: Adjusting Air Conditioning Temperature Settings

Boan Biotech has successfully optimized the temperature and humidity settings of the air conditioning system in the cleanroom area. While maintaining the standard of 18-26°C temperature and 45-65% humidity, we adjusted the settings to 20°C/50% in winter and 24°C/60% in summer. This adjustment has resulted in an annual electricity saving of 137,357 kWh for the 7,000 m^2 cleanroom area, equivalent to reducing 73.71 tonnes of CO_2 emissions. It significantly improves energy use efficiency while ensuring the quality of the production environment.

Case: Optimizing Chiller System Operation

Boan Biotech has achieved significant energy savings by optimizing the operation mode of the chiller system. We implemented intelligent control of the cooling towers, dynamically adjusting the fan operation based on actual load to avoid overcooling. Additionally, we established an "on-demand start/stop" mechanism for the ethylene glycol unit, which starts 30 minutes before use and is turned off immediately after use. These measures have resulted in an annual electricity saving of approximately 3,700 kWh for the ethylene glycol pump and a combined saving of 6,600 kWh for the two cooling tower fans, totaling 10,300 kWh, equivalent to reducing CO_2 emissions by 5.53 tonnes. This practice not only fulfills the requirements of the ISO 50001 system but also lays the foundation for future intelligent control upgrades and waste heat recovery.

Boan Biotech has made significant progress in environmental sustainability. In December 2024, we passed the clean production audit and acceptance, which fully demonstrates our excellence in green manufacturing and environmental production practices. Additionally, our new construction projects smoothly passed the environmental impact assessment review by the Yantai Municipal Ecological Environment Bureau during the Reporting Period. We will continue to implement the pollution control and ecological protection measures proposed in the environmental impact report to mitigate and control adverse environmental impacts.

Clean Production Audit – Preparation Workshop and Drug Substance Workshop

7.2 AIR EMISSIONS & WASTE MANAGEMENT

Under the global wave of sustainable development, biopharmaceutical companies bear a special environmental mission. Deeply understanding its key role in ecological protection, Boan Biotech not only strictly complies with national environmental protection laws and regulations, such as the Law of the People's Republic of China on the Prevention and Control of Air Pollution and the Law of the People's Republic of China on the Prevention and Control of Water Pollution, but also proactively adopts international environmental standards and the stricter local environmental regulations and industry best practices to demonstrate the Company's environmental leadership.

To achieve harmonious development between operational activities and ecological balance, Boan Biotech has established a systematic environmental management system. We have formulated internal policies such as the Waste Management Procedures. Through scientific control mechanisms for wastewater, exhaust gas, and solid waste, we continuously optimize emission reduction technologies and resource recycling efficiency. In particular, in the waste treatment process, we implement regulations such as the Waste Treatment Regulations and the Emergency Response System for Hazardous Chemical Leakage to strictly monitor the entire lifecycle of waste from generation to final disposal.

In terms of actual implementation, general waste generated in the production process (such as recyclable packaging materials and cartons) is delivered to urban environmental protection agencies for unified treatment. For hazardous waste, including waste reagent bottles, medical waste, waste culture media, and office ink cartridges, we rigorously select third-party institutions with professional qualifications for safe disposal to ensure compliance with non-hazardous standards. In addition, we have updated our discharge permit during the Reporting Period, and all emissions meet national and local environmental protection standards.

For detailed environmental performance data, please refer to the Environmental KPIs Table in the appendix. Our EHS protection measures in relation to operations and manufacturing include:

EHS Protection Measures in Relation to Boan Biotech's Operations and Manufacturing

1. Strictly comply with GMP certification regulations and relevant pollutant discharge standards in the production process to reduce the discharge of air, wastewater and other pollutants;

2. Implement safety guidelines on employees' health and safety, environmental protection as well as operation of laboratory and production facilities and production safety, and closely monitor internal compliance with these guidelines; and

3. Appoint qualified third parties to dispose of all hazardous wastes arising from R&D and production activities in accordance with applicable laws and regulations.

Air Emissions & Waste Management Targets and Actions of Boan Biotech

Waste reduction target: Hazardous waste generation ≤ 35 tonnes

Measures taken

- The penicillin bottles generated during the experimental process in the preparation workshops are first washed, crushed, and then disposed of as general waste to reduce the disposal amount of hazardous waste; and
- Reasonably control the purchase quantity of chemical reagents to reduce the amount of obsolete scrapped products.

Emission reduction target: Standard emission of volatile organic compounds (VOCs)

Measures taken

- Waste collection and disposal devices are regularly maintained to ensure their normal operation; and
- Entrust a qualified third party to monitor the exhaust gas every six months.

Case: Quality Control Department – Hazardous Waste Training

To enhance employees' awareness of hazardous waste management, Boan Biotech organised training sessions for relevant staff. The training content included an analysis of the specific management requirements for hazardous waste, an emphasis on the legal responsibilities for compliant storage, labelling, and transportation. Through this training, Boan Biotech further strengthened the environmental compliance foundation in the quality control process, providing assurance for the achievement of the "zero pollution incidents" target.

7.3 WATER RESOURCES

Boan Biotech fully recognises the preciousness of water resources and always prioritises water resource protection in environmental management. We strictly adhere to the requirements of relevant regulations, such as the Water Law of the People's Republic of China, and have established a comprehensive water resource management system. Through systematic water-saving measures and wastewater recycling mechanisms, we ensure the rational use and effective protection of water resources. In our operations, we rigorously implement wastewater treatment procedures, ensuring that all discharged water quality meets national and local environmental standards. There were no water resource-related issues during the Reporting Period.

In terms of specific implementation, we fully implement water-saving principles and the practice of using water for multiple purposes, such as industrial production water, equipment cooling water, cleaning water, and domestic water. We also regularly commission professional third-party testing institutions to conduct wastewater quality monitoring and assessment, maintaining high standards of water quality management.

7.4 ENERGY USE & CLIMATE CHANGE

As the challenges of global climate change become increasingly severe, corporate participation in climate action has become an indispensable responsibility. China's 14th Five-Year Plan clearly proposed the strategic goal of "achieving carbon peaking by 2030 and carbon neutrality by 2060," establishing a clear path for the country's sustainable development and setting new standards for corporate operations. Deeply understanding the urgency of climate action, Boan Biotech actively integrates ESG risk management strategies into corporate operations, systematically identifying and responding to the physical and transition risks brought about by climate change. In research and development and production, we continuously promote process optimization, effectively reducing the impact of operational activities on the climate through specific measures such as improving energy efficiency and reducing resource consumption, demonstrating the Company's determination in climate governance.

Physical risks	Transformation risks
Our production facilities in the coastal area of Yantai, Shandong may be affected by extreme weather events and natural disasters that may occur as a result of climate change	In the context of policy trends towards low-carbon, high-efficiency and green transformation, the government may impose higher low-carbon technology requirements on companies, resulting in higher operating costs. For instance, upgrades in production processes aimed at energy saving and emission reduction may increase the investment costs of the Company

Case: Flood Prevention Drill for Chemical Reagent Warehouse

To address potential risks during the flood season, Boan Biotech conducted a flood emergency drill for the chemical reagent storage warehouse in August 2024. The drill simulated a scenario of typhoon and heavy rain, focusing on key procedures such as "rapid deployment of flood sandbags," "emergency relocation of hazardous chemicals," and "emergency response to leaked reagents," while also testing the coordination efficiency of the drainage system.

In the face of the increasingly severe challenges of global climate change, Boan Biotech actively responds to the trend of green development and is committed to transforming environmental concepts into concrete actions. To effectively address the challenges posed by climate change, we have established a comprehensive energy management system that uses digital technology to precisely monitor and manage the consumption of resources such as water and electricity. This has significantly improved energy efficiency and continuously reduced the environmental load during our operations.

Furthermore, we commissioned a professional third-party institution to conduct a comprehensive review of greenhouse gas emissions in our operations and to carry out a carbon footprint assessment for our key products during the year. These professional evaluations not only help us to more accurately identify the sources of environmental impact but also provide important basis for formulating scientific carbon reduction strategies in the future. Through systematic data collection and analysis, we are able to continuously optimize every link in the product lifecycle and move towards a lower-carbon operational model.

Greenhouse Gas Verification and Product Carbon Footprint Declaration


经纬方达

温室气体核查声明

济南经纬方达节能技术有限公司

2024 年 04 月 22 日


经纬方达

产品碳足迹声明

At the same time, by setting clear environmental goals and implementing systematic energy-saving and emission-reduction measures, we continuously enhance employees' environmental awareness. We persistently promote the full implementation of environmental protection concepts in all aspects of corporate operations and regularly assess environmental management performance to ensure that all environmental measures achieve maximum effectiveness.

7.5 PACKAGING MATERIALS MANAGEMENT

Boan Biotech adheres to a sustainable development strategy in the field of product packaging, integrating environmental concepts into every link from raw material selection, production processes to logistics and transportation. We strictly follow relevant environmental regulations and systematically achieve packaging lightweighting and improved resource efficiency through innovative packaging design, process optimization, and transportation management systems. Currently, our product packaging primarily uses recyclable carton materials. Meanwhile, we continuously strengthen supply chain collaboration, reduce the consumption of raw and auxiliary materials as well as packaging materials through precise material management, and prioritise the use of environmentally certified materials. Looking forward, we will continue to develop more environmentally friendly packaging solutions and take concrete actions to reduce the impact on the ecological environment.

8 EHS SYSTEM AND SAFE PRODUCTION

In the daily operations of Boan Biotech, we always uphold the EHS management philosophy of "protecting the environment and safeguarding the health and safety of employees." Referring to international benchmark management standards and combining the actual operational conditions and business environment of the Company, we continuously improve the integrated EHS management system. To effectively regulate all management practices related to environmental protection, occupational health, and safety within the Company, we have clearly stipulated relevant implementation measures in the EHS Manual. This not only lays a solid foundation for achieving EHS policy objectives but also specifically demonstrates our active commitment to environmental and social responsibility. By deeply integrating the EHS concept into every aspect of corporate culture and operations, the following is an overview of our EHS principles, commitments, and targets:

EHS Principles

"Focus on environmental and occupational health and safety to ensure sustainable development"

- Strive to protect the environment, health and safety of employees, establish an environmental and occupational health and safety management system, and adhere to a source control approach with an emphasis on prevention
- Committed to strict compliance with laws and regulations, meet the expectations of stakeholders to the greatest extent, maintain open communication
- Dedicated to continuous improvement and enhancement, upholding innovation in technology and management

EHS Commitment

Maintain and take effective measures to continuously improve the management system

- Correct and prevent any deviation from the environmental and occupational health and safety policy and environmental and occupational health and safety target
- All employees shall follow our EHS policy, EHS target and commitment

EHS Targets

Maintain the normal operation and continuous improvement of the integrated EHS management system

- The Company established an EHS target system that includes general target and sub-target for each department to ensure the smooth operation of management and the continuous improvement of environmental and occupational health and safety performance
- At the beginning of each year, set the annual targets and indicators according to the overall business targets and the characteristics of the project construction, and properly apply them to the relevant departments/projects based on the allocation of responsibilities, as the basis of control and assessment for the year

8 EHS SYSTEM AND SAFE PRODUCTION

EHS MANAGEMENT SYSTEM

Actively responding to national environmental protection policies, Boan Biotech has established a dedicated Safety and Environmental Protection Department. This department is responsible for overseeing the implementation of policies and regulations related to fire safety, safety production supervision, and environmental protection, and for formulating safety production and operation standards tailored to the Company's characteristics. The Company requires all management personnel and employees to strictly comply with laws, regulations, and internal policies in the fields of environment, health, and safety. By clarifying job responsibilities and implementing various management measures, we collectively build a safe, healthy, and environmentally friendly working environment.

We strictly adhere to the requirements of occupational health and safety regulations and have established a comprehensive EHS management system in accordance with the ISO 14001:2015 Environmental Management System and the ISO 45001:2018 Occupational Health and Safety Management System standards. The EHS Safety Manual serves as a guiding document, providing health and safety guidance for employees' daily work and effectively preventing occupational hazards. Additionally, we have established a three-tier emergency response system, which includes comprehensive emergency plans, special emergency plans, and on-site response plans. This ensures that effective measures can be taken swiftly in the event of an emergency to minimize losses and environmental impacts.

EHS MANAGEMENT PLAN

In accordance with our EHS management policies, commitments, and targets, the Safety and Environmental Protection Department of our Company is responsible for formulating the EHS management plan and conducting regular reviews. To ensure the effective achievement of annual safety and environmental goals and indicators, this department implements quarterly supervisory inspections. It assesses the implementation and effectiveness of the environmental and occupational health and safety management plans and truthfully reports the results to the management representatives.

In terms of the content of the plan, we clearly specify the details of each action plan, including key elements such as the allocation of responsibilities and the implementation timeline. The plan covers the duties that various functional departments and management levels must undertake to achieve the targets, the specific methods and technical measures adopted, and the necessary resource allocation, thereby ensuring the feasibility and successful implementation of the plan.

ENVIRONMENTAL FACTORS, HAZARDOUS SOURCE IDENTIFICATION, RISK ASSESSMENT, AND RISK CONTROL PLANNING

The Company identifies significant environmental factors and major risk items in its operational activities through systematic procedures for the identification of environmental factors, hazardous source identification, and risk assessment. In particular, we conduct comprehensive control over intolerable risks that may cause environmental impacts or occupational safety hazards. Based on this, the Safety and Environmental Protection Department has formulated the Procedures for the Identification of Environmental Factors, Hazardous Source Identification, and Risk Assessment and Control. Each department follows such procedures to identify environmental factors and hazardous sources and to assess and select key risk items that may have significant impacts on environmental protection or occupational health and safety.

Environmental factors	Hazardous sources
• Emissions to the air and water • Waste management • Soil pollution • Community impact • Use of raw materials, resources, and energy	• Activities that may cause personnel injuries • Occupationally induced disease • Property loss or operational disruptions

We have taken different measures to safeguard the health and safety of our employees, contractors, suppliers, customers, as well as visitors to our business premises and production bases in the community. The relevant measures include:

- Implementing a safety production responsibility system to enhance supervision and management of the production process, with the aim of preventing and reducing production safety accidents, ensuring the safety of employees' lives and protecting property from damage;

- Strictly adhering to Good Manufacturing Practice (GMP) and relevant environmental emission standards to reduce air pollution, wastewater discharge and other environmental pollutions;

- Implementing occupational health and safety and environmental protection guidelines that cover operational safety in laboratories and production facilities, while also closely monitoring compliance with these guidelines;

- In accordance with the law, we entrust qualified third-party vendors and institutions with the handling of hazardous waste generated during research and development and production processes to meet legal and regulatory requirements.

Exterior of Boan Biotech Manufacturing Center

8.1 SAFE PRODUCTION

As an industry-leading biotechnology company, Boan Biotech has a profound understanding of the environmental, health, and safety risks associated with our research and development and operational activities. We not only strictly comply with domestic and international environmental protection and occupational health and safety regulations but have also established a comprehensive internal management system. Through institutionalized policies and procedures, we ensure the effective implementation of all regulations.

In the corporate governance structure, the Chief Executive Officer is directly responsible for overseeing matters related to social responsibility, employee health, workplace safety, and environmental protection. The scope of management includes: the process safety and hazardous materials management system, the safety production responsibility system, employee health and safety regulations, and the responsibilities of the Safety and Environmental Protection Department, among others, to ensure that the Company's operations fully comply with regulatory requirements.

We are committed to creating a safe research and working environment, which is not only reflected in the protection of all employees but also extends to the rights and interests of subjects participating in clinical trials. Accident prevention and reporting mechanisms, among other safety guidelines, are included as core content in the training of new employees. At the same time, we strictly require that subjects in clinical trials be fully informed about safety information before participating in the trial and at all necessary times to safeguard their right to be informed and their safety interests.

To continuously optimize the occupational health and safety environment, we have implemented multiple safeguard measures, including the formulation of the Employee Health and Labour Protection Management Regulations, adherence to safety operating procedures in line with GMP standards, and regular comprehensive safety assessments of laboratories and production facilities. Through these rigorous standard operating procedures and inspection mechanisms, we ensure that all operational aspects meet the highest standards of safety and environmental protection.

Production safety-related policy documents	
Health and Safety	Health and Safety Training and Hidden Hazard Identification
• Production safety responsibility system • Production safety meeting management system • Occupational health and supervision management system • Personal labour protection equipment management procedures • Fire management system • Special operation personnel management system • Emergency management system • Emergency response plan for production safety accidents • Special equipment operator management system • Dangerous goods management procedures	• Production Safety Inspection System • EHS Education and Training System • Hidden Hazard Identification and Management System • Safety Risk Classification and Control System • Hidden Hazard Reporting and Whistleblower Reward System

Boan Biotech has established a systematic safety risk prevention and control system. Through the Production Safety Inspection System and the Accident Hidden Hazard Identification and Management System, it has clearly defined the frequency, implementation methods, and responsibilities at various levels for safety inspections, conducting comprehensive and multi-level hidden hazard identification and rectification in production and business premises. In terms of safety culture building, the Company strictly implements the Environment, Health and Safety (EHS) Education and Training System, with professional departments regularly organizing safety knowledge training for employees. The training content includes key aspects such as safe operating procedures, emergency response procedures, and the use of personal protective equipment, continuously enhancing employees' safety awareness and risk prevention capabilities.

To safeguard employees' occupational health, the Company has established a comprehensive occupational health surveillance system, including regular occupational health examinations and monitoring of the working environment, effectively preventing the occurrence of occupational diseases. For employees diagnosed with occupational diseases, the Company strictly provides reasonable job adjustment plans and corresponding compensation in accordance with relevant regulations. During the Reporting Period, Boan Biotech recorded no work-related fatalities or lost days due to work injury.

Case: Emergency Evacuation Drill

In June 2024, we organized a fire evacuation drill. All personnel completed key steps such as smoke sheltering, low-crawl evacuation, and emergency exit identification within a specially designed “evacuation training module” that simulated real-fire conditions.

8.2 CHEMICALS MANAGEMENT

Boan Biotech's production bases undertake high-standard research and development, quality control, and routine maintenance tasks, which often involve the use of various hazardous chemicals. To ensure safe production, we have established a stringent protection system, with a particular focus on key aspects such as fire prevention and electric shock prevention. During high-risk operations (such as the dismantling of lye pipelines), we strictly provide professional protective equipment such as protective masks and emergency eyewash stations to ensure the safety of employees in both routine operations and emergency situations.

We strictly abide by the Production Safety Law of the People's Republic of China and other relevant regulations, and have clearly defined safety management responsibilities based on the Departmental Responsibilities of the Manufacturing Department. The Safety and Environmental Protection Department is not only responsible for implementing national and Company's production safety and environmental protection policies, regulations, and systems, but also closely follows the latest directives from government authorities such as fire protection, safety supervision, and environmental protection. The department promptly communicates and implements these requirements, actively participates in the formulation of the Company's production safety regulations and operating procedures, and provides professional safety and environmental management advice in the Company's operational decision-making process. This ensures that all departments and employees strictly fulfill their production safety responsibilities and continuously improve the Company's safety protection system.

Boan Biotech was selected as a Level 3 Enterprise for Production Safety Standardisation of Hazardous Chemicals (the eighth batch in 2021)



烟台市应急管理局

烟应急专〔2021〕56号

关于公布危险化学品从业单位安全生产标准化三级企业名单（2021年第八批）的通知

各区市应急局，各有关企业，有关安全标准化咨询和评审单位：

根据《危险化学品从业单位安全生产标准化评审标准》（安监总管三〔2011〕93号）、《关于危险化学品从业单位安全生产标准化评审工作有关事项的通知》（安监总办〔2016〕111号）和《关于认真做好危险化学品企业安全生产标准化达标创建和评审工作的通知》（鲁安监发〔2011〕150号）等有关规定，经企业自评、申请、评审单位评审和应急部门审核，现将准烟台中福石油销售有限公司等14家企业为危险化学品从业单位安全生产标准化三级企业，有效期自公布之日起3年。

附件：危险化学品从业单位安全生产标准化三级企业名单

烟台市应急管理局

2021年11月1日

In accordance with the Evaluation Standards for Safety Production Standardisation of Hazardous Chemical Enterprises of the People's Republic of China (AJZGS No. [2011] 93), the Notice on Matters Relating to the Evaluation Work on Safety Production Standardisation of Hazardous Chemical Enterprises (AJZB [2016] No. 111) and the Notice on Seriously Doing a Good Job in Standard Creation and Evaluation of Safety Production Standardisation of Hazardous Chemical Enterprises (LAJF [2011] No. 150) and other relevant provisions, 14 enterprises, including Boan Biotech, were accredited as a Level 3 enterprise for production safety standardisation of hazardous chemicals, upon self-evaluation, application of the enterprises, evaluation by evaluation agencies and audit by emergency departments. The validity period is 3 years effective from the date of the notice.

Case: Emergency Drill for Hazardous Chemical Waste Leakage

To enhance the capability of responding to hazardous chemical waste leakage, Boan Biotech conducted a full-scale practical drill in March 2024, simulating a leakage accident. Relevant staff members were organized to participate in the entire process to comprehensively test the feasibility of the emergency response plan and the efficiency of team collaboration in handling the accident.

9 PEOPLE ORIENTATION

Boan Biotech firmly believes that employees are its most valuable asset and the core engine driving innovation and sustainable development. To create a people-oriented workplace ecosystem, we are committed not only to building a safe, healthy, and inclusive working environment, but also to developing a comprehensive system that covers the entire employment management process, multidimensional career development, and all-round employee care from the perspective of talent strategy. Through systematic talent cultivation and development plans, we pave diversified growth paths for employees, empowering them to unlock their potential across innovation and R&D, professional excellence, and management capabilities. Through refined human resources management, we ensure every employee's rights are respected, needs addressed, and contributions recognized, achieving a win-win scenario where individual career aspirations align with corporate development goals.

Number of Employees
(by gender)



Number of Employees
(by employment type)



Number of Employees
(by job title)



Number of Employees
(by age group)



Number of Employees
(by geographical region)



9 PEOPLE ORIENTATION

During the Reporting Period, Boan Biotech had a total of 760 employees, including 758 full-time employees and 2 part-time employees. The number of employees of the Company by gender, employment type, employee category, age group, and geographical region, is shown as follows:

Number of Employees		
By gender	Male employees	274
	Female employees	486
By employment type	Full-time employees	758
	Part-time employees	2
By employee category (by job title)	Directors and senior managers	24
	Managers and supervisors	55
	Other employees	681
By age group	Aged 18-25	132
	Aged 26-35	413
	Aged 36-45	185
	Aged 46-55	24
	Aged 56 and above	6
By geographical region	Chinese Mainland	755
	Overseas	5

During the Year, the employee turnover rate of Boan Biotech by gender, age group and geographical region is shown as follows[1]:

Employee turnover rate		Number	Percentage %
By gender	Male employees	32	11.68%
	Female employees	45	9.26%
By age group	Aged 18-25	35	26.52%
	Aged 26-35	33	7.99%
	Aged 36-45	7	3.78%
	Aged 46-55	1	4.17%
	Aged 56 and above	1	16.67%
By geographical region	Chinese Mainland	77	10.20%
	Overseas	0	0%

[1] Calculation formula for employee turnover rate: Number of resigning employees in this category / Total number of employees in this category x 100%.

9 PEOPLE ORIENTATION

9.1 EMPLOYMENT MANAGEMENT

Recruitment, dismissal and promotion

Boan Biotech strictly adheres to relevant laws and regulations, including the Labour Law of the People's Republic of China, the Labour Contract Law of the People's Republic of China, the Employment Promotion Law of the People's Republic of China, and the Contract Law of the People's Republic of China. We have established a comprehensive human resources management system that upholds the principles of "selecting outstanding talents, fairly assessing performance, and fully unlocking potential" and implements a fair and just employment mechanism. We have formulated the Recruitment and Interview Management System, which clearly stipulates the processes for salary structure, dismissal procedures, talent recruitment, and promotion channels. We consistently follow our recruitment principles of "openness, fairness, competition and merit-based" and have strict regulations on recruitment procedures, salary grade and position determination, and induction arrangements.

All recruited employees enter into employment contracts in accordance with the Labour Contract Management System, which details the term of employment, job responsibilities, working hours, and termination conditions to protect employees' rights in accordance with the laws. Meanwhile, we implement the Remuneration and Welfare Management System to establish a competitive remuneration system and a fair and transparent performance evaluation mechanism. Through reasonable incentive measures, we enhance work efficiency. Boan Biotech is committed to fostering a workplace environment that values employees' contributions and sense of achievement, providing continuous professional growth and development platforms to realize mutual advancement for both individuals and the Company.

Working hours, holidays, equal opportunities, diversity, anti-discrimination and other benefits and welfare

Boan Biotech adheres to the core values of equality, diversity, and anti-discrimination, regarding each employee as a valuable asset to the Company's development. We sincerely respect the diverse cultural backgrounds and customs of our employees and strictly follow the principle of fairness in all aspects of human resources management, including talent recruitment, career development, promotion evaluation, training systems, and incentive mechanisms. We eliminate any discriminatory treatment based on race, ethnicity, age, gender, religious belief, or physical condition. We actively build an inclusive workplace ecosystem, promote the integration of diverse cultures, and create a work atmosphere of mutual respect and complementary strengths. This not only enhances employees' sense of belonging and happiness but also gathers diverse talents for the Company's sustainable development.

In terms of compliance, Boan Biotech strictly implements laws and regulations such as the Law of the People's Republic of China on the Protection of Women's Rights and Interests and the Law of the People's Republic of China on the Protection of Persons with Disabilities, and firmly opposes any discriminatory practices. The Human Resources Department of the Company has formulated the Working Hours and Leave Management System for Employees in accordance with the laws, which clearly defines standard working hours, rest and leave policies, and fully protects employees' labour rights and interests.

Elimination of child labour and forced labour

Boan Biotech strictly complies with the Law of the People's Republic of China on the Protection of Minors and the Regulations on the Prohibition of Child Labour and fully regulates its employment management to resolutely eliminate child labour and forced labour. In terms of specific implementation, our Human Resources Department strictly controls the recruitment process, establishes a legal working age verification mechanism, and checks job applicants' identity documents through the system to ensure that all recruited personnel meet the national minimum employment age standards. For potential child labour employment situations, the Company has established a complete emergency handling procedure. Once a violation is found, the employment relationship will be immediately terminated, a special investigation mechanism will be launched to trace the root of the problem, and an effective rectification plan will be implemented. At the same time, we continuously strengthen the enforcement of the system and optimize the preventive review system to effectively prevent such violations.

During the Reporting Period, we did not have any breach of laws and regulations relating to employment and labour practices, nor did we find any incident of child labour or forced labour.

9.2 TALENT TRAINING

Boan Biotech always adheres to the philosophy that "employees are the most valuable asset of the Company" and strives to build a top-notch team with professional quality and innovation capabilities through a systematic talent cultivation mechanism and diversified career development channels. To effectively enhancing employee capabilities in line with corporate strategic goals, we have customised a talent training system that meets our business development needs. Through a comprehensive training framework and personalised development plans, we promote employee career growth and organisational innovation simultaneously.

Boan Biotech Recognised as "Best Practice Enterprise in Training Technology" by AACTP

In November 2024, Boan Biotech was awarded the "Best Practice Enterprise in Training Technology" at the 2nd AACTP China Training Technology Festival, in recognition of its excellent practices and continuous innovation in the field of training.

9 PEOPLE ORIENTATION

To promote continuous learning and growth among employees, we have established a comprehensive learning and communication platform, covering a wide range of activities such as industry technology seminars, professional skills workshops, and cross-departmental project competitions. These measures not only strengthen the collaboration among team members but also effectively stimulate employees' innovative potential and enthusiasm for technical exchanges. At the same time, we actively encourage employees to participate in external academic seminars and professional certification courses to continuously introduce cutting-edge knowledge and advanced technologies, and comprehensively enhance the innovation competitiveness of individuals and teams. Through such a complete training and development strategy, Boan Biotech aims to build a learning organisation and lay a solid foundation for maintaining technological leadership and competitive advantages in the rapidly changing industry environment.

Boan Biotech adopts a comprehensive training model of "induction training, facilitator guidance, and on-the-job mentoring" to provide growth opportunities for fresh graduates and help them unleash their potential. To continuously optimize the talent cultivation mechanism and closely integrate employee professional development with corporate strategic goals, we have formulated the Management System for External Training Programmes. Based on the professional requirements of different job categories and the future development direction of the Company, this system allocates a special education budget annually to systematically support employees' participation in various training programmes. The training options we offer cover multiple aspects, including:

- Online and offline training provided by external institutions (including: PMP and other certification qualification exams);

- On-the-job education courses (including: on-the-job postgraduate courses, MBA or EMBA training).

Any employee who meets the training requirements may apply for training in accordance with the system's approval process, subject to review and approval.

9 PEOPLE ORIENTATION

Boan Biotech adheres to the concept of balancing talent cultivation with business development. The Human Resources Department, together with various business units, has formulated a targeted Annual Training Plan, which covers pre-job training, on-the-job training, and off-the-job training, as well as the specific implementation of training content.

Pre-job training	**On-boarding training** • Corporate culture, policies and regulations, products or services and areas of business of the Company, getting to know the office environment, etc. • GMP (2010 revision), Pharmaceutical Administration Law, microbiology knowledge, pharmacovigilance, workshop and laboratory safety, and other professional knowledge **Induction training** • Job responsibilities, position-related SOP documents, mastering relevant knowledge and skills for the position
Job training	**Basic training** • Pharmaceutical Administration Law, quality control standards including GMP/GLP/GCP, microbiology knowledge, safety knowledge, and computerized knowledge training **Professional training** • SOP documents, pharmaceutical regulations, EHS systems, computer systems, management skills, etc.
Off-job training	Participating in external training activities organised by government authorities, industry associations, training institutions, etc., including specialized training courses, seminars, public lectures, overseas study tours, and other external training events

Case: First Phase of Action Learning Empowerment Camp

During the Reporting Period, Boan Biotech organised a series of courses for management personnel titled the Action Learning Empowerment Camp. Each management personnel, combining the knowledge gained from the courses with their work priorities, conducted research on cost reduction and efficiency improvement projects centred around the management requirements of "delivering high value, achieving high returns, and mitigating high risks". This initiative truly enabled them to gain valuable insights and apply their learning effectively, continuously enhancing their capabilities in problem-solving, team management, and project management through the integration of learning and practice.

Case: Boan Lecture Series

In January, April, and August 2024, Boan Biotech meticulously planned a series of training courses under the Boan Lecture Series, themed "Yantai's New Starting Point as a Trillion-RMB City: Embarking on a New Journey of Dreams", "Pathways and M&A Strategies for International Business Expansion in Pharmaceuticals", and "Review and Outlook of the Global Pharmaceutical Market" respectively. These courses were designed for in-depth discussions on relevant topics.

Boan Biotech has established a comprehensive and multi-level training curriculum system based on different job characteristics and individual development needs. This includes customised induction training for new college graduate employees, management training programmes, project management skills, job-specific training, as well as courses on workplace culture and communication skills. These meticulously planned training programs aim to help employees continuously improve their professional competencies and adaptability in the rapidly changing industry environment.

During the year, the employee training data of Boan Biotech are as follows[2]:

		Number of employees trained	Percentage of employees trained
By gender	Male employees	260	35.37%
	Female employees	475	64.63%
By employee category (by job title)	Directors and senior managers	24	3.27%
	Managers and supervisors	55	7.48%
	Other employees	656	89.25%

		Average training hours (hour)	Total training hours (hour)
By gender	Male employees	71.4	19,552
	Female employees	76.8	37,335
By employee category (by job title)	Directors and senior managers	60.0	1,440
	Managers and supervisors	58.4	3,212
	Other employees	75.6	51,496

[2] The percentage of employees trained by relevant category is calculated by dividing the number of employees trained in that category by the total number of employees trained; the average training hours of employees by relevant category is calculated by dividing the total training hours of employees in that category by the total number of employees in that category.

9.3 EMPLOYEE CARE

Boan Biotech not only strictly implements the basic welfare guarantees stipulated by the state but also strives to build a comprehensive employee care system. We have meticulously designed a series of welfare programmes aimed at creating a workplace environment filled with humanistic care, where every employee can fully unlock their potential and achieve self-fulfilment.

Holiday benefits	To provide employees with certain holiday benefits during traditional holidays in some countries, including the Chinese New Year, Women's Day, Mid-Autumn Festival, Children's Day, etc.
Commercial insurance	To strengthen the protection of employee health by providing inpatient and outpatient medical insurance, 24-hour personal accident insurance and critical illness insurance.
Annual physical examination	To organise a physical examination every year and establish health records for employees.
Employee mutual assistance guarantee plan	An employee mutual assistance guarantee fund was established to assist employees suffering various accidents and major family hardships. In addition to assisting employees in obtaining statutory benefits and commercial insurance, a certain amount of money will be granted from the mutual assistance fund to help employees and their families to tide over their difficulties.
Wedding gift money	To prepare wedding gift money for newly married employees.
Rewards for excellence	Annual commendations at the Company level and the subsidiary level are held every year to reward employees and teams with outstanding performance and to encourage employees to actively participate in practical projects with innovative value.
Other employee benefits	Such as birthday benefits, childcare fees, long-term service awards, etc.

In terms of the comprehensive development of employees, we have specifically planned a diverse range of team activities, including regularly held fitness clubs, employee birthday celebrations, themed team activities, lectures on healthy lifestyles, and warm family days. These activities not only enhance employees' physical fitness but also promote emotional communication and collaboration among team members, effectively improving employees' physical and mental health.

Case: Lantern Festival Celebration

On the occasion of the Lantern Festival, Boan Biotech specially planned a "Celebrating the Lantern Festival" themed celebration. The event featured a variety of traditional games, including the highly folkloric ring-toss game and other interactive segments. The hosting of this event not only enriched the employees'extracurricular cultural life but also enhanced team cohesion, showcasing the Company's people-oriented corporate culture philosophy.

Case: "Around the World Team Challenge" Team-building Activity

In October 2024, Boan Biotech successfully hosted the "Around the World Team Challenge" themed team-building activity. Aimed at alleviating work pressure, stimulating creativity, and deepening cross-departmental communication and collaboration through immersive experiences and team challenges, this activity injected vitality into the sustainable development of the Company.

10 COMMUNITY CONTRIBUTIONS

Boan Biotech has always regarded corporate social responsibility as a core mission. With the philosophy of "innovative healthcare for the benefit of humanity", we continuously promote the development of the medical and health industry. Leveraging our expertise in the biopharmaceutical field, we provide better treatment options for global patients through innovative drug research and development and the sharing of medical resources. Among these efforts, the Boyounuo Patient Relief Project continued to be a significant philanthropic initiative for the Group in 2024, helping numerous economically disadvantaged patients access necessary high-quality medical services and significantly improving their health conditions and quality of life.

Case: Boyounuo Patient Relief Project



医药筹- 博优诺®患者救助 项目
2024 年捐赠协议

甲方：山东博安生物技术股份有限公司（以下简称“甲方”）
地址：山东省烟台市高新区科技大道 39 号
联系人：[redacted]

乙方：北京康盟慈善基金会（以下简称乙方）
地址：北京市朝阳区安华里五区 21 号楼四层 417 号
联系人：[redacted]

In line with our commitment to corporate social responsibility, the Group continued to sign donation agreements with the Beijing Health Alliance Charitable Foundation and other organisations in 2024, donating bevacizumab injections in batches. This programme, implemented through a national public welfare network, provides precise drug assistance to effectively alleviate the financial burden of patients with serious illnesses and helps to improve the social medical relief system.

Looking ahead, we will further deepen our investment in areas such as environmental protection and community public welfare, continuously expanding the coverage and influence of our public welfare projects. Through close cooperation with medical institutions and public welfare organisations, we are committed to building a more comprehensive medical relief system to benefit more vulnerable groups.

Case: 2024 Spring Arbor Day

In the spring of 2024, Boan Biotech organised an Arbor Day event for employees and their families. By planting trees together, we put environmental protection into practice and significantly enhanced employees'awareness of ecological protection.

Case: "Junior Researcher" Programme

Adhering to the educational philosophy of scientific enlightenment, Boan Biotech launched the "Junior Researcher" science popularisation experience activity during the Reporting Period. Through carefully designed experimental demonstrations and interactive segments, children were given the opportunity to get up close and personal with the basic knowledge of the bioscience field.

APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE

ENVIRONMENTAL KPIS TABLE[3]

Environmental KPIs Summary Table of Boan Biotech in 2024			Previous data
	Unit	Data in FY2024	Data in FY2023
Air Emissions[4]			
Nitrogen oxides (NO_x)	kilograms	–	0.04
Sulphur oxides (SO_x)	kilograms	–	0.04
Carbon monoxide (CO)	kilograms	–	1.06
Fine particulate matter (PM2.5)	kilograms	–	0.007
Inhalable particulate matter (PM10)	kilograms	–	0.007
Energy consumption[5]			
Total direct energy consumption	'000 kWh	–	2.24
Direct energy consumption intensity[6]	'000 kWh/Revenue in RMB'000	–	0.0000036
Total indirect energy consumption	'000 kWh	30,263.30	29,343.20
Indirect energy consumption intensity	'000 kWh/Revenue in RMB'000	0.042	0.047
Gasoline			
Total consumption	litres	–	241
Total consumption	'000 kWh	–	2.24
Consumption intensity	'000 kWh/Revenue in RMB'000	–	0.0000036
Outsourced electricity			
Total consumption	'000 kWh	10,916.40	10,782.41
Consumption intensity	'000 kWh/Revenue in RMB'000	0.015	0.017
Outsourced industrial steam			
Total consumption	tonnes	26,137.00	25,075.00
Total consumption	'000 kWh	19,346.90	18,560.81
Consumption intensity	'000 kWh/Revenue in RMB'000	0.027	0.030
Water			
Total consumption	m^3	160,910.00	159,936.00
Consumption intensity	m^3/Revenue in RMB'000	0.22	0.26
Packaging materials			
Total consumption	tonnes	25.31	0
Consumption intensity	tonnes/Revenue in RMB'000	0.0000348	0

3 The statistical scope of environmental data for FY2024 is Boan Biotech Yantai Production Base.

4 The Group's primary source of air emissions stems from emissions generated by official vehicle operations. During the Reporting Period, the Group did not use any vehicles and has thus eliminated air emissions.

5 The total energy consumption of the Group includes gasoline, outsourced electricity and outsourced industrial steam consumption, and the calculation method is based on the "Accounting Methods and Reporting Guidelines for Greenhouse Gas Emissions of Enterprises in Other Industries" (Trial).

6 The density calculation is based on the Group's annual revenue per RMB'000 as the denominator. The Group's total revenue for the year was RMB726,316,000.

Environmental KPIs Summary Table of Boan Biotech in 2024			Previous data
	Unit	Data in FY2024	Data in FY2023
GHG emissions (Scope 1 and 2)			
Emissions from refrigerants (Scope 1)[7]	tonnes	397.80	0
Emissions from industrial steam usage (Scope 2)[8]	tonnes	7,661.37	7,350.07
Emissions from purchased electricity (Scope 2)[9]	tonnes	5857.74	6,149.22
Total GHG emissions	tonnes	13,916.91	13,499.85
Total GHG emissions intensity	tonnes/Revenue in RMB'000	0.019	0.022
Production wastewater discharge			
Production wastewater discharge[10]	tonnes	158,702.00	91,571.60
Production wastewater discharge intensity	tonnes/Revenue in RMB'000	0.22	0.15
Non-hazardous waste produced[11]			
Total production	tonnes	3.450	3.678
Total recovery	tonnes	3.45	3.68
Production intensity	tonnes/Revenue in RMB'000	0.0000047	0.0000060

7 The calculation of GHG emissions from refrigerants (Scope 1) is based on the "Sixth Assessment Report on Climate Change" issued by the Intergovernmental Panel on Climate Change (IPCC).

8 The calculation of GHG emissions from industrial steam (Scope 2) is based on the "Accounting Methods and Reporting Guidelines for Greenhouse Gas Emissions of Enterprises in Other Industries" (Trial) issued by the National Development and Reform Commission.

9 The calculation of greenhouse gas emissions from purchased electricity (Scope 2) is based on the national average carbon dioxide emission factor for electricity in 2022, as specified in the "Announcement on the 2022 Carbon Dioxide Emission Factor for Electricity" published by the Ministry of Ecology and Environment of China and the National Bureau of Statistics.

10 In 2024, certain newly constructed projects of the Group entered the trial operation phase. Due to process flow testing and equipment run-in requirements, wastewater discharge generated during production processes increased significantly compared to 2023.

11 The non-hazardous waste categories included in the Group's statistics for 2024 are paper and outer packaging cartons.

Environmental KPIs Summary Table of Boan Biotech in 2024			Previous data
	Unit	Data in FY2024	Data in FY2023
Hazardous waste produced			
Total production	tonnes	33.77	32.50
Total production intensity	tonnes/Revenue in RMB'000	0.000046	0.000053
Medical waste			
Total production	tonnes	14.17	12.62
Waste culture media	tonnes	11.34	10.65
Waste biological drugs	tonnes	1.98	1.97
Other medical waste	tonnes	0.85	–
Production intensity	tonnes/Revenue in RMB'000	0.000020	0.000020
Organic waste liquid			
Total production	tonnes	0.66	0.54
Production intensity	tonnes/Revenue in RMB'000	0.00000090	0.00000087
Waste reagent bottles and packages			
Total production	tonnes	18.21	18.90
Production intensity	tonnes/Revenue in RMB'000	0.000025	0.000031
Waste mineral oil and lubricating oil			
Total production[12]	tonnes	–	0.08
Production intensity	tonnes/Revenue in RMB'000	–	0.00000013
Laboratory waste			
Total production	tonnes	0.74	0.36
Production intensity	tonnes/Revenue in RMB'000	0.00000101	0.00000059

[12] Since the lubricating oil for the equipment has not reached its replacement cycle, the generation of waste mineral oil and lubricating oil is nil this year.

SOCIAL KPIS TABLE[13]

Social KPIs Summary Table of Boan Biotech in 2024			
Employment			
			Number
By gender	**Total workforce**		760
	Male employees		274
	Female employees		486
By employment type	Full-time employees		758
	Part-time employees		2
By age group	Aged 18-25		132
	Aged 26-35		413
	Aged 36-45		185
	Aged 46-55		24
	Aged 56 and above		6
By geographical region	Chinese Mainland		755
	Overseas		5
Number and rate of employee turnover			
		Number	**Percentage**
By gender	Male employees	32	11.68%
	Female employees	45	9.26%
By age group	Aged 18-25	35	26.52%
	Aged 26-35	33	7.99%
	Aged 36-45	7	3.78%
	Aged 46-55	1	4.17%
	Aged 56 and above	1	16.67%
By geographical region	Chinese Mainland	77	10.20%
	Overseas	0	0%

[13] The statistical scope of social data for FY2024 is within the Group. Unless otherwise specified, the statistical scope of social data of the Group for the year is consistent with that for FY2023.

Health and Safety

Number of work-related fatalities

	2024	2023	2022	
Number of work-related fatalities	0	0	0	Person

Lost days due to work injury

	2024	2023	2022	
Lost days due to work injury of employees of the Company	0	0	0	Day
Rate of work-related fatalities	0	0	0	%

Occupational Health and Safety Measures

Number of employees participating in safety training during the Reporting Period	More than 5,000	Person

Development and Training

Percentage of Employees Trained

		Number	Percentage of Employees Trained
By gender	Male employees	260	35.37%
	Female employees	475	64.63%
By employee category (by job title)	Directors and senior managers	24	3.27%
	Managers and supervisors	55	7.48%
	Other employees	656	89.25%

Training hours

		Average hours (hour)	Total training hours (hour)
By gender	Male employees	71.4	19,552
	Female employees	76.8	37,335
By employee category (by job title)	Directors and senior managers	60.0	1,440
	Managers and supervisors	58.4	3,212
	Other employees	75.6	51,496

Supply Chain Management			
Number of suppliers			
Suppliers		Supplier	1,912
By geographical region	Domestic	Supplier	1,833
	Overseas	Supplier	79
Product Responsibility			
Percentage of products sold subject to recalls			
Total number of products sold during the Reporting Period		Vial	840,200
Percentage of products sold subject to recalls		Percentage	0%
Number of complaints			
Number of complaints		Case	3
Anti-corruption			
Number of legal cases regarding corrupt practices			
Number of concluded legal cases regarding corrupt practices brought against the Company during the Reporting Period		Case	0
Number of concluded legal cases regarding corrupt practices brought against the employees during the Reporting Period		Case	0
Community Investment			
Resources Contributed			
Amount of donations to local communities (including direct and indirect) donations of materials and cash during the Reporting Period		Donation of bevacizumab injections to Beijing Health Alliance Charitable Foundation	

APPENDIX II CONTENT INDEX OF THE ESG REPORTING GUIDE

Mandatory Disclosure Requirements	Description	Relevant Section or Statement in this Report
Governance Structure	A statement from the Board containing the following elements: (i) a disclosure of the Board's oversight of ESG issues; (ii) the Board's ESG management approach and strategy, including the process used to evaluate, prioritise and manage material ESG-related issues (including risks to the issuer's businesses); and (iii) how the Board reviews progress made against ESG-related goals and targets with an explanation of how they relate to the issuer's businesses.	4.1 Sustainable Development Concept
Reporting Principles	A description of, or an explanation on, the application of the following Reporting Principles in the preparation of the ESG Report: **Materiality:** The issuer should make a report when the ESG issues determined by the Board become sufficiently important to investors and other stakeholders. **Quantitative:** KPIs in respect of historical data need to be measurable. The issuer should set targets (which may be actual numerical figures or directional, forward-looking statements) to reduce a particular impact. In this way the effectiveness of ESG policies and management systems can be evaluated and validated. Quantitative information should be accompanied by a narrative, explaining its purpose, impacts, and giving comparative data where appropriate. **Consistency:** The issuer should use consistent methodologies to allow for meaningful comparisons of ESG data over time.	2.3 Reporting Principles
Reporting Boundary	A narrative explaining the reporting boundaries of the ESG Report and describing the process used to identify which entities or operations are included in the ESG Report. If there is a change in the scope, the issuer should explain the difference and reason for the change.	2.2 Reporting Boundary

General Disclosures and KPIs	Description	Relevant Section or Statement in this Report
Environmental		
Aspect A1: Emissions		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer; relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	7.2 Air Emissions & Waste Management
KPI A1.1	The types of emissions and respective emissions data.	APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI A1.2	Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI A1.5	Description of emission target(s) set and steps taken to achieve them.	7.2 Air Emissions & Waste Management
KPI A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	7.2 Air Emissions & Waste Management

General Disclosures and KPIs	Description	Relevant Section or Statement in this Report
Environmental		
Aspect A2: Use of Resources		
General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	7 Green Home
KPI A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	7.4 Energy Use & Climate Change During the Reporting Period, the Company has systematically implemented various energy-saving measures, effectively reducing the energy consumption for production and the energy intensity per unit. In the next year, we will continue to review the setting of targets.
KPI A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	7.3 Water Resources The Company is not in a water-intensive industry, and has encountered no issues in sourcing water. In the next year, we will continue to review the setting of targets.
KPI A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	7.5 Packaging Materials Management APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE

General Disclosures and KPIs	Description	Relevant Section or Statement in this Report
Environmental		
Aspect A3: The Environment and Natural Resources		
General Disclosure	Policies on minimising the issuer's significant impacts on the environment and natural resources.	7 Green Home
KPI A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	7 Green Home
Aspect A4: Climate Change		
General Disclosure	Policies on identification and mitigation of significant climate-related issues which have impacted, and those which may impact, the issuer.	7.4 Energy Use & Climate Change
KPI A4.1	Description of the significant climate-related issues which have impacted, and those which may impact, the issuer, and the actions taken to manage them.	7.4 Energy Use & Climate Change
Social		
Employment and Labour Practices		
Aspect B1: Employment		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer; relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	9.1 Employment Management
KPI B1.1	Total workforce by gender, employment type (for example, full – or part-time), age group and geographical region.	9.1 Employment Management APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI B1.2	Employee turnover rate by gender, age group and geographical region.	9.1 Employment Management APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE

General Disclosures and KPIs	Description	Relevant Section or Statement in this Report
Social		
Aspect B2: Health and Safety		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer; relating to providing a safe working environment and protecting employees from occupational hazards	8.1 Occupational Health and Safety
KPI B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	8.1 Occupational Health and Safety APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI B2.2	Lost days due to work injury.	8 EHS SYSTEM AND SAFE PRODUCTION APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	8 EHS SYSTEM AND SAFE PRODUCTION

General Disclosures and KPIs	Description	Relevant Section or Statement in this Report
Social		
Aspect B3: Development and Training		
General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	9.2 Talent Training
KPI B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	9.2 Talent Training APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI B3.2	The average training hours completed per employee by gender and employee category.	9.2 Talent Training APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
Aspect B4: Labour Standards		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer; relating to preventing child and forced labour.	9.1 Employment Management
KPI B4.1	Description of measures to review employment practices to avoid child and forced labour.	9.1 Employment Management
KPI B4.2	Description of steps taken to eliminate such practices when discovered.	9.1 Employment Management

General Disclosures and KPIs	Description	Relevant Section or Statement in this Report
Social		
Operating Practices		
Aspect B5: Supply Chain Management		
General Disclosure	Policies on managing environmental and social risks of the supply chain.	6.2 Supply Chain Management
KPI B5.1	Number of suppliers by geographical region.	6.2 Supply Chain Management APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	6.2 Supply Chain Management
KPI B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	6.2 Supply Chain Management
KPI B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	6.2 Supply Chain Management

General Disclosures and KPIs	Description	Relevant Section or Statement in this Report
Social		
Aspect B6: Product Responsibility		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer; relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	5.3 Drug Sales and Customer Service Management
KPI B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	5.3 Drug Sales and Customer Service Management APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI B6.2	Number of products and service related complaints received and how they are dealt with.	5.3 Drug Sales and Customer Service Management APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI B6.3	Description of practices relating to observing and protecting intellectual property rights.	5.1 Product Innovation & Protection of Scientific Research Achievements
KPI B6.4	Description of quality assurance process and recall procedures.	5.3 Drug Sales and Customer Service Management
KPI B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	5.3 Drug Sales and Customer Service Management

General Disclosures and KPIs	Description	Relevant Section or Statement in this Report
Social		
Aspect B7: Anti-corruption		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer; relating to bribery, extortion, fraud and money laundering.	4.3 Integrity and Compliance
KPI B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	4.3 Integrity and Compliance APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE
KPI B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	4.3 Integrity and Compliance
KPI B7.3	Description of anti-corruption training provided to directors and staff.	4.3 Integrity and Compliance The Group conducted anti-corruption training for the Board and employees in 2023, but no training was arranged in 2024. The Legal Department will continue to deepen employees' professional knowledge in anti-corruption and compliance management in the future.
Community		
Aspect B8: Community Investment		
General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	10 Community Contributions
KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	10 Community Contributions
KPI B8.2	Resources contributed (e.g. money or time) to the focus area.	10 Community Contributions APPENDIX I ENVIRONMENTAL AND SOCIAL KPIS TABLE

Boan Biotech
博安生物